HRP20120334T1 - Supstituirani piperidino-dihidrotienopirimidini - Google Patents

Supstituirani piperidino-dihidrotienopirimidini Download PDF

Info

Publication number: HRP20120334T1
Authority: HR; Croatia
Prior art keywords: methyl; ethyl; alkylene; methylene; phenyl
Prior art date: 2007-10-19

Application number

HRP20120334AT

Other languages

English (en)

Croatian (hr)

Inventor

Pouzet Pascale

Anderskewitz Ralf

Dollinger Horst

Fiegen Dennis

Fox Thomas

Goeggel Rolf

Hoenke Christoph

Martyres Domnic

Nickolaus Peter

Klinder Klaus

Original Assignee

Boehringer Ingelheim International Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-19

Filing date

2012-04-16

Publication date

2012-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154006&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120334(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-04-16 Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh

2012-05-31 Publication of HRP20120334T1 publication Critical patent/HRP20120334T1/hr

Links

JMUGMZBGUVOSPU-UHFFFAOYSA-N 1-piperidin-1-yl-2h-thieno[3,2-d]pyrimidine Chemical class C1CCCCN1N1C(C=CS2)=C2C=NC1 JMUGMZBGUVOSPU-UHFFFAOYSA-N 0.000 title 1
-1 -het Chemical group 0.000 claims abstract 88
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 55
150000001875 compounds Chemical class 0.000 claims abstract 52
125000001072 heteroaryl group Chemical group 0.000 claims abstract 49
108010081348 HRT1 protein Hairy Proteins 0.000 claims abstract 48
102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims abstract 48
VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims abstract 48
JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims abstract 47
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 41
125000004043 oxo group Chemical group O=* 0.000 claims abstract 41
229920006395 saturated elastomer Polymers 0.000 claims abstract 31
125000002950 monocyclic group Chemical group 0.000 claims abstract 30
125000005842 heteroatom Chemical group 0.000 claims abstract 20
229910052717 sulfur Inorganic materials 0.000 claims abstract 20
229910052736 halogen Inorganic materials 0.000 claims abstract 19
150000002367 halogens Chemical class 0.000 claims abstract 19
229910052760 oxygen Inorganic materials 0.000 claims abstract 19
125000000041 C6-C10 aryl group Chemical group 0.000 claims abstract 17
125000000623 heterocyclic group Chemical group 0.000 claims abstract 17
125000002619 bicyclic group Chemical group 0.000 claims abstract 14
229910052757 nitrogen Inorganic materials 0.000 claims abstract 12
125000000753 cycloalkyl group Chemical group 0.000 claims abstract 6
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims abstract 3
125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims abstract 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 133
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 61
239000005977 Ethylene Substances 0.000 claims 58
229910052731 fluorine Inorganic materials 0.000 claims 57
229910052801 chlorine Inorganic materials 0.000 claims 56
239000000460 chlorine Substances 0.000 claims 56
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 56
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 55
150000003839 salts Chemical class 0.000 claims 44
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 43
150000004677 hydrates Chemical class 0.000 claims 43
239000012453 solvate Substances 0.000 claims 43
229910052794 bromium Inorganic materials 0.000 claims 39
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 39
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 25
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 18
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 12
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 10
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 10
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 10
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 9
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 9
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 9
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 9
239000011737 fluorine Substances 0.000 claims 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
201000010099 disease Diseases 0.000 claims 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
239000003814 drug Substances 0.000 claims 5
229910052739 hydrogen Inorganic materials 0.000 claims 5
125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 4
229940079593 drug Drugs 0.000 claims 4
238000004519 manufacturing process Methods 0.000 claims 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 4
OPKQXJQFEPNJTP-UHFFFAOYSA-N 1-phenylpropa-1,2-dienylbenzene Chemical group C=1C=CC=CC=1C(=C=C)C1=CC=CC=C1 OPKQXJQFEPNJTP-UHFFFAOYSA-N 0.000 claims 3
125000004070 6 membered heterocyclic group Chemical group 0.000 claims 3
230000001154 acute effect Effects 0.000 claims 3
125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 claims 3
239000003112 inhibitor Substances 0.000 claims 3
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 3
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 3
125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
PKORYTIUMAOPED-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinazoline Chemical compound C1=CC=C2NCNCC2=C1 PKORYTIUMAOPED-UHFFFAOYSA-N 0.000 claims 2
HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 claims 2
208000020925 Bipolar disease Diseases 0.000 claims 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
208000002193 Pain Diseases 0.000 claims 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
208000028683 bipolar I disease Diseases 0.000 claims 2
210000003169 central nervous system Anatomy 0.000 claims 2
125000002541 furyl group Chemical group 0.000 claims 2
LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 claims 2
125000001624 naphthyl group Chemical group 0.000 claims 2
230000000414 obstructive effect Effects 0.000 claims 2
230000002093 peripheral effect Effects 0.000 claims 2
210000001428 peripheral nervous system Anatomy 0.000 claims 2
SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 claims 2
230000002265 prevention Effects 0.000 claims 2
125000004076 pyridyl group Chemical group 0.000 claims 2
230000000241 respiratory effect Effects 0.000 claims 2
208000023504 respiratory system disease Diseases 0.000 claims 2
125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims 1
CXIPCVGKMMYCCL-UHFFFAOYSA-N 1-cyclopropylpropa-1,2-dienylcyclopropane Chemical group C1CC1C(=C=C)C1CC1 CXIPCVGKMMYCCL-UHFFFAOYSA-N 0.000 claims 1
LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 claims 1
KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 claims 1
UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 claims 1
CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 claims 1
KDYWHKGSKGUIQO-UHFFFAOYSA-N 3,4,4a,5-tetrahydro-2h-1,2-benzoxazine Chemical compound C1C=CC=C2ONCCC21 KDYWHKGSKGUIQO-UHFFFAOYSA-N 0.000 claims 1
BGDOLELXXPTPFX-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzoxazine Chemical compound C1=CC=C2ONCCC2=C1 BGDOLELXXPTPFX-UHFFFAOYSA-N 0.000 claims 1
208000019901 Anxiety disease Diseases 0.000 claims 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
208000000094 Chronic Pain Diseases 0.000 claims 1
206010009137 Chronic sinusitis Diseases 0.000 claims 1
206010009900 Colitis ulcerative Diseases 0.000 claims 1
208000011231 Crohn disease Diseases 0.000 claims 1
NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical compound C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 claims 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
208000018522 Gastrointestinal disease Diseases 0.000 claims 1
206010019196 Head injury Diseases 0.000 claims 1
206010021143 Hypoxia Diseases 0.000 claims 1
206010061218 Inflammation Diseases 0.000 claims 1
208000019693 Lung disease Diseases 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 claims 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
208000018737 Parkinson disease Diseases 0.000 claims 1
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
208000006011 Stroke Diseases 0.000 claims 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
208000030886 Traumatic Brain injury Diseases 0.000 claims 1
201000006704 Ulcerative Colitis Diseases 0.000 claims 1
239000013543 active substance Substances 0.000 claims 1
208000005298 acute pain Diseases 0.000 claims 1
239000000808 adrenergic beta-agonist Substances 0.000 claims 1
125000002947 alkylene group Chemical group 0.000 claims 1
239000005557 antagonist Substances 0.000 claims 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
125000003118 aryl group Chemical group 0.000 claims 1
208000006673 asthma Diseases 0.000 claims 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 1
230000003454 betamimetic effect Effects 0.000 claims 1
125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
208000025307 bipolar depression Diseases 0.000 claims 1
230000006931 brain damage Effects 0.000 claims 1
231100000874 brain damage Toxicity 0.000 claims 1
208000029028 brain injury Diseases 0.000 claims 1
201000011510 cancer Diseases 0.000 claims 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
239000000812 cholinergic antagonist Substances 0.000 claims 1
230000001684 chronic effect Effects 0.000 claims 1
208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
239000003246 corticosteroid Substances 0.000 claims 1
229960001334 corticosteroids Drugs 0.000 claims 1
229940121647 egfr inhibitor Drugs 0.000 claims 1
YIWFBNMYFYINAD-UHFFFAOYSA-N ethenylcyclopropane Chemical group C=CC1CC1 YIWFBNMYFYINAD-UHFFFAOYSA-N 0.000 claims 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
230000007954 hypoxia Effects 0.000 claims 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
208000027866 inflammatory disease Diseases 0.000 claims 1
230000002757 inflammatory effect Effects 0.000 claims 1
230000004054 inflammatory process Effects 0.000 claims 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
230000003843 mucus production Effects 0.000 claims 1
201000006417 multiple sclerosis Diseases 0.000 claims 1
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
DTHHUAXKOMWYBI-UHFFFAOYSA-N oxadiazolidine Chemical compound C1CONN1 DTHHUAXKOMWYBI-UHFFFAOYSA-N 0.000 claims 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
210000002345 respiratory system Anatomy 0.000 claims 1
201000000980 schizophrenia Diseases 0.000 claims 1
125000003003 spiro group Chemical group 0.000 claims 1
OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 claims 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Oncology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HRP20120334AT 2007-10-19 2012-04-16 Supstituirani piperidino-dihidrotienopirimidini HRP20120334T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07118901		2007-10-19
PCT/EP2008/063999 WO2009050248A1 (de)	2007-10-19	2008-10-16	Substituierte piperidino-dihydrothienopyrimidine

Publications (1)

Publication Number	Publication Date
HRP20120334T1 true HRP20120334T1 (hr)	2012-05-31

Family

ID=39154006

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HRP20120334AT HRP20120334T1 (hr)	2007-10-19	2012-04-16	Supstituirani piperidino-dihidrotienopirimidini
HRP20141153AT HRP20141153T1 (hr)	2007-10-19	2014-11-26	Supstituirani piperidino-dihidrotieno-pirimidini

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HRP20141153AT HRP20141153T1 (hr)	2007-10-19	2014-11-26	Supstituirani piperidino-dihidrotieno-pirimidini

Country Status (34)

Country	Link
US (1)	US8754073B2 (zh)
EP (3)	EP2215092B1 (zh)
JP (2)	JP5150728B2 (zh)
KR (1)	KR101548975B1 (zh)
CN (2)	CN101827852B (zh)
AR (1)	AR069075A1 (zh)
AT (1)	ATE542825T1 (zh)
AU (1)	AU2008313660B2 (zh)
BR (1)	BRPI0818006B8 (zh)
CA (1)	CA2705414C (zh)
CL (1)	CL2008003096A1 (zh)
CY (2)	CY1112703T1 (zh)
DK (2)	DK2610258T3 (zh)
EA (1)	EA019480B1 (zh)
EC (1)	ECSP10010156A (zh)
ES (2)	ES2381452T3 (zh)
HK (1)	HK1145677A1 (zh)
HR (2)	HRP20120334T1 (zh)
MA (1)	MA31845B1 (zh)
ME (1)	ME01330B (zh)
MX (1)	MX2010004026A (zh)
MY (1)	MY153979A (zh)
NZ (1)	NZ585346A (zh)
PE (2)	PE20131463A1 (zh)
PL (2)	PL2215092T3 (zh)
PT (2)	PT2610258E (zh)
RS (1)	RS52271B (zh)
SI (2)	SI2610258T1 (zh)
TN (1)	TN2010000175A1 (zh)
TW (1)	TWI421077B (zh)
UA (1)	UA99309C2 (zh)
UY (1)	UY31405A1 (zh)
WO (1)	WO2009050248A1 (zh)
ZA (1)	ZA201001683B (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1847543A1 (de)	2006-04-19	2007-10-24	Boehringer Ingelheim Pharma GmbH & Co. KG	Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
AU2008312624B2 (en)	2007-10-18	2014-07-10	Boehringer Ingelheim International Gmbh	Preparation of dihydrothieno [3, 2-D] pyrimidines and intermediates used therein
CA2702518A1 (en)	2007-10-19	2009-04-23	Boehringer Ingelheim International Gmbh	New piperazino-dihydrothienopyrimidine derivatives
CA2705414C (en) *	2007-10-19	2016-05-24	Boehringer Ingelheim International Gmbh	Substituted piperidino-dihydrothienopyrimidines
NZ585348A (en)	2007-10-19	2012-02-24	Boehringer Ingelheim Int	Heterocycle-substituted piperazino-dihydrothienopyrimidines
EP2400962B1 (de)	2009-02-27	2017-11-08	Boehringer Ingelheim International GmbH	Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
WO2011124524A1 (de)	2010-04-08	2011-10-13	Boehringer Ingelheim International Gmbh	Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
WO2011124525A1 (de)	2010-04-08	2011-10-13	Boehringer Ingelheim International Gmbh	Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
US9365539B2 (en)	2010-05-11	2016-06-14	Merck Sharp & Dohme Corp.	Prolylcarboxypeptidase inhibitors
US9802954B2 (en)	2011-08-24	2017-10-31	Boehringer Ingelheim International Gmbh	Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) *	2011-08-24	2013-03-07	Boehringer Ingelheim International Gmbh	Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9013997B2 (en) *	2012-06-01	2015-04-21	Broadcom Corporation	System for performing distributed data cut-through
US9499519B2 (en)	2012-12-26	2016-11-22	Medivation Technologies, Inc.	Fused pyrimidine compounds and use thereof
ES2637716T3 (es)	2013-02-04	2017-10-16	Grünenthal GmbH	Nuevos compuestos de pirimidina condensados sustituidos
WO2014124860A1 (en)	2013-02-14	2014-08-21	Boehringer Ingelheim International Gmbh	Specific pde4b-inhibitors for the treatment of diabetes mellitus
HUP1300139A2 (en) *	2013-03-06	2014-09-29	Richter Gedeon Nyrt	Phenoxypiperidine h3 antagonists
CN104892720B (zh) *	2014-03-07	2016-10-26	华东师范大学	4,4-二甲基石胆酸-2,3-骈n-芳基吡唑衍生物及其制备方法和应用
WO2018003962A1 (ja) *	2016-06-30	2018-01-04	国立研究開発法人理化学研究所	新規化合物又はその薬理学的に許容される塩
CN111108109A (zh) *	2017-09-20	2020-05-05	利奥制药有限公司	取代的二氢噻吩并嘧啶及其作为磷酸二酯酶抑制剂的用途
EP3700529A1 (en)	2017-10-23	2020-09-02	Boehringer Ingelheim International GmbH	New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
CN111712502B (zh)	2017-12-15	2023-10-27	联合疗法公司	取代的氮杂环丁烷二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途
JP7201688B2 (ja) *	2017-12-15	2023-01-10	ユニオン・セラピューティクス・アクティエセルスカブ	置換テトラヒドロピランジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
FI3724196T3 (fi) *	2017-12-15	2023-01-31		Substituoituja atsetidiinidihydrotienopyridiinejä ja niiden käyttö fosfodiesteraasin estäjinä
WO2020048827A1 (en) *	2018-09-03	2020-03-12	Bayer Aktiengesellschaft	1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2023104958A1 (en)	2021-12-09	2023-06-15	Boehringer Ingelheim International Gmbh	New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
AU2022404695A1 (en)	2021-12-09	2024-05-02	Boehringer Ingelheim International Gmbh	New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
WO2023232135A1 (zh) *	2022-06-02	2023-12-07	西藏海思科制药有限公司	Pde4b抑制剂及其用途
WO2023241684A1 (zh) *	2022-06-16	2023-12-21	武汉人福创新药物研发中心有限公司	Pde4b抑制剂
CN115040503B (zh) *	2022-07-26	2023-10-10	云南民族大学	螺环二烯酮型木脂素类化合物在制药中的应用
WO2024032673A1 (zh) *	2022-08-09	2024-02-15	西藏海思科制药有限公司	Pde4b抑制剂及其用途
WO2024068386A1 (en)	2022-09-28	2024-04-04	Boehringer Ingelheim International Gmbh	Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor
WO2024067660A1 (zh) *	2022-09-29	2024-04-04	苏州爱科百发生物医药技术有限公司	氮杂稠环类化合物、其制备方法及其在医药上的应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1470336A1 (de)	1962-07-04	1969-03-20	Thomae Gmbh Dr K	Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL124131C (zh)	1963-06-17
DE1470356A1 (de)	1964-01-15	1970-04-30	Thomae Gmbh Dr K	Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
NL123139C (zh)	1965-03-31
BE754606A (fr)	1969-08-08	1971-02-08	Thomae Gmbh Dr K	Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
DE2032687A1 (en)	1970-07-02	1972-01-05	Dr. Karl Thomae Gmbh, 7950 Biberach	Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
DE1940572A1 (de)	1969-08-08	1971-02-11	Thomae Gmbh Dr K	Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US3763156A (en)	1970-01-28	1973-10-02	Boehringer Sohn Ingelheim	2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (zh)	1970-03-18	1971-12-10	Westinghouse Freins & Signaux
DE2121950A1 (en)	1971-05-04	1972-11-23	Dr. Karl Thomae Gmbh, 7950 Biberach	Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de)	1977-11-10	1979-05-17	Thomae Gmbh Dr K	Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en)	1979-06-11	1981-03-17	Syntex (U.S.A.) Inc.	Long acting depot injectable formulations for LH-RH analogues
US5187168A (en)	1991-10-24	1993-02-16	American Home Products Corporation	Substituted quinazolines as angiotensin II antagonists
US5491201A (en)	1992-02-06	1996-02-13	The Dow Chemical Company	Mesogenic cyclic imino ether-containing compositions and polymerization products thereof
JPH07330777A (ja)	1994-06-08	1995-12-19	Taisho Pharmaceut Co Ltd	チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
JPH09301958A (ja)	1996-05-09	1997-11-25	Nippon Shoji Kk	新規ピリミジン化合物及び抗ロタウイルス剤
US6339089B2 (en)	1997-08-13	2002-01-15	Fujirebio Inc.	Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
JP2003520042A (ja)	2000-01-24	2003-07-02	アイシス・ファーマシューティカルス・インコーポレーテッド	誘導性一酸化窒素シンターゼ発現のアンチセンスモジュレーション
GB0004153D0 (en)	2000-02-23	2000-04-12	Astrazeneca Uk Ltd	Novel use
MEP40008A (en)	2000-10-12	2011-02-10	Boehringer Ingelheim Pharma	Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
DE10064994A1 (de)	2000-12-23	2002-07-04	Merck Patent Gmbh	Sulfamidothienopyrimidine
CN100343258C (zh)	2001-04-30	2007-10-17	美国拜尔公司	新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物
AR035700A1 (es)	2001-05-08	2004-06-23	Astrazeneca Ab	Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
KR101011353B1 (ko)	2001-06-22	2011-01-28	베링거 잉겔하임 파르마 게엠베하 운트 코 카게	결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US6587548B2 (en)	2001-07-17	2003-07-01	Hewlett-Packard Development Co., L.P.	Method and system of using a single telephone number for multiple services
WO2003055890A1 (en)	2001-12-21	2003-07-10	Bayer Pharmaceuticals Corporation	Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2003059913A1 (en)	2002-01-10	2003-07-24	Bayer Healthcare Ag	Roh-kinase inhibitors
SE0203304D0 (sv)	2002-11-07	2002-11-07	Astrazeneca Ab	Novel Coumpounds
OA13050A (en)	2003-04-29	2006-11-10	Pfizer Ltd	5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
WO2004104179A2 (en)	2003-05-16	2004-12-02	Wisconsin Alumni Research Foundation	Method for isolating and cloning high molecular weight polynucleotide molecules from the environment
JP2005003345A (ja)	2003-05-21	2005-01-06	Showa Denko Kk	換気兼熱交換装置および空調システム
CN103834699A (zh)	2003-10-02	2014-06-04	Dsmip资产公司	使用改进量的氯和钾在微藻类中产生高水平的dha
MY141220A (en)	2003-11-17	2010-03-31	Astrazeneca Ab	Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20050137186A1 (en)	2003-12-18	2005-06-23	Abbott Gmbh & Co. Kg.	Tetrahydrobenzazepines and their use
EP1701951B1 (en)	2003-12-23	2010-02-10	Serodus AS	Modulators of peripheral 5-ht receptors
WO2005082865A1 (ja)	2004-02-27	2005-09-09	Astellas Pharma Inc.	縮合二環性ピリミジン誘導体
GB0427403D0 (en)	2004-12-15	2005-01-19	Astrazeneca Ab	Novel compounds I
KR20080005601A (ko)	2005-05-11	2008-01-14	니코메드 게엠베하	Ｐｄｅ４ 억제제 로플루밀라스트와 테트라히드로비오프테린유도체의 조합
EP1874781B9 (de)	2006-04-19	2010-09-08	Boehringer Ingelheim International GmbH	Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP1847543A1 (de)	2006-04-19	2007-10-24	Boehringer Ingelheim Pharma GmbH & Co. KG	Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
KR101567096B1 (ko)	2007-04-20	2015-11-06	글락소 그룹 리미티드	항균제로서의 트리시클릭 질소 함유 화합물
AU2008312624B2 (en)	2007-10-18	2014-07-10	Boehringer Ingelheim International Gmbh	Preparation of dihydrothieno [3, 2-D] pyrimidines and intermediates used therein
EP2214673B1 (de)	2007-10-19	2012-05-30	Boehringer Ingelheim International GmbH	Phenyl-substituierte piperazino-dihydrothienopyrimidine
FR2922550B1 (fr)	2007-10-19	2009-11-27	Sanofi Aventis	Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
CA2705414C (en) *	2007-10-19	2016-05-24	Boehringer Ingelheim International Gmbh	Substituted piperidino-dihydrothienopyrimidines
BRPI0818605A2 (pt)	2007-10-19	2015-04-22	Schering Corp	Derivados de 1,3,4-tiadiazl espiro-condensados para inibir a atividade de ksp cinesima
NZ585348A (en)	2007-10-19	2012-02-24	Boehringer Ingelheim Int	Heterocycle-substituted piperazino-dihydrothienopyrimidines
AU2008312055A1 (en)	2007-10-19	2009-04-23	Astrazeneca Ab	Tetrazole derivatives as modulators of metabotropic glutamate receptors (mGluRs)
CA2702518A1 (en)	2007-10-19	2009-04-23	Boehringer Ingelheim International Gmbh	New piperazino-dihydrothienopyrimidine derivatives
EP2400962B1 (de)	2009-02-27	2017-11-08	Boehringer Ingelheim International GmbH	Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
EP2400961B1 (de)	2009-02-27	2017-11-22	Boehringer Ingelheim International GmbH	Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
US20130059866A1 (en)	2011-08-24	2013-03-07	Boehringer Ingelheim International Gmbh	Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma

2008
- 2008-10-16 CA CA2705414A patent/CA2705414C/en active Active
- 2008-10-16 KR KR1020107010905A patent/KR101548975B1/ko active IP Right Grant
- 2008-10-16 DK DK13154790.3T patent/DK2610258T3/da active
- 2008-10-16 SI SI200831314T patent/SI2610258T1/sl unknown
- 2008-10-16 ES ES08839793T patent/ES2381452T3/es active Active
- 2008-10-16 PT PT131547903T patent/PT2610258E/pt unknown
- 2008-10-16 AT AT08839793T patent/ATE542825T1/de active
- 2008-10-16 EP EP08839793A patent/EP2215092B1/de active Active
- 2008-10-16 PL PL08839793T patent/PL2215092T3/pl unknown
- 2008-10-16 EP EP11174754.9A patent/EP2380891B1/de active Active
- 2008-10-16 SI SI200830579T patent/SI2215092T1/sl unknown
- 2008-10-16 US US12/738,344 patent/US8754073B2/en active Active
- 2008-10-16 PT PT08839793T patent/PT2215092E/pt unknown
- 2008-10-16 DK DK08839793.0T patent/DK2215092T3/da active
- 2008-10-16 EP EP13154790.3A patent/EP2610258B1/de active Active
- 2008-10-16 MX MX2010004026A patent/MX2010004026A/es active IP Right Grant
- 2008-10-16 JP JP2010529389A patent/JP5150728B2/ja active Active
- 2008-10-16 ES ES13154790.3T patent/ES2524910T3/es active Active
- 2008-10-16 CN CN200880112254.5A patent/CN101827852B/zh active Active
- 2008-10-16 AU AU2008313660A patent/AU2008313660B2/en active Active
- 2008-10-16 RS RS20120144A patent/RS52271B/en unknown
- 2008-10-16 ME MEP-2012-26A patent/ME01330B/me unknown
- 2008-10-16 CN CN201410312258.5A patent/CN104069112A/zh active Pending
- 2008-10-16 PL PL13154790T patent/PL2610258T3/pl unknown
- 2008-10-16 NZ NZ585346A patent/NZ585346A/en unknown
- 2008-10-16 MY MYPI2010001693A patent/MY153979A/en unknown
- 2008-10-16 WO PCT/EP2008/063999 patent/WO2009050248A1/de active Application Filing
- 2008-10-16 EA EA201000609A patent/EA019480B1/ru not_active IP Right Cessation
- 2008-10-16 BR BRPI0818006A patent/BRPI0818006B8/pt active IP Right Grant
- 2008-10-16 UA UAA201005780A patent/UA99309C2/ru unknown
- 2008-10-17 PE PE2013001391A patent/PE20131463A1/es not_active Application Discontinuation
- 2008-10-17 AR ARP080104560A patent/AR069075A1/es active IP Right Grant
- 2008-10-17 UY UY31405A patent/UY31405A1/es not_active Application Discontinuation
- 2008-10-17 TW TW097139983A patent/TWI421077B/zh active
- 2008-10-17 PE PE2008001796A patent/PE20091386A1/es not_active Application Discontinuation
- 2008-10-17 CL CL2008003096A patent/CL2008003096A1/es unknown
2010
- 2010-03-09 ZA ZA201001683A patent/ZA201001683B/xx unknown
- 2010-04-16 TN TN2010000175A patent/TN2010000175A1/fr unknown
- 2010-05-05 EC EC2010010156A patent/ECSP10010156A/es unknown
- 2010-05-12 MA MA32832A patent/MA31845B1/fr unknown
- 2010-12-22 HK HK10111978.1A patent/HK1145677A1/zh not_active IP Right Cessation
2012
- 2012-04-16 HR HRP20120334AT patent/HRP20120334T1/hr unknown
- 2012-04-23 CY CY20121100378T patent/CY1112703T1/el unknown
- 2012-12-03 JP JP2012264647A patent/JP5615889B2/ja active Active
2014
- 2014-11-26 CY CY20141100984T patent/CY1115858T1/el unknown
- 2014-11-26 HR HRP20141153AT patent/HRP20141153T1/hr unknown

Also Published As

Publication number	Publication date
JP2011500640A (ja)	2011-01-06
PE20131463A1 (es)	2013-12-23
JP5615889B2 (ja)	2014-10-29
EA201000609A1 (ru)	2010-10-29
DK2610258T3 (da)	2014-11-10
PE20091386A1 (es)	2009-10-17
PT2215092E (pt)	2012-04-10
EP2380891A1 (de)	2011-10-26
CN101827852B (zh)	2014-07-30
CN104069112A (zh)	2014-10-01
WO2009050248A1 (de)	2009-04-23
CL2008003096A1 (es)	2010-02-12
BRPI0818006B8 (pt)	2021-05-25
PL2215092T3 (pl)	2012-07-31
RS52271B (en)	2012-10-31
MY153979A (en)	2015-04-30
AU2008313660B2 (en)	2013-11-07
CY1112703T1 (el)	2016-02-10
HRP20141153T1 (hr)	2015-02-13
AR069075A1 (es)	2009-12-30
ECSP10010156A (es)	2010-06-29
BRPI0818006B1 (pt)	2019-10-22
KR101548975B1 (ko)	2015-09-01
KR20100100807A (ko)	2010-09-15
UA99309C2 (ru)	2012-08-10
JP5150728B2 (ja)	2013-02-27
MA31845B1 (fr)	2010-11-01
CA2705414C (en)	2016-05-24
PT2610258E (pt)	2014-10-24
PL2610258T3 (pl)	2015-02-27
CN101827852A (zh)	2010-09-08
CA2705414A1 (en)	2009-04-23
SI2215092T1 (sl)	2012-04-30
NZ585346A (en)	2011-09-30
ES2524910T3 (es)	2014-12-15
ES2381452T3 (es)	2012-05-28
DK2215092T3 (da)	2012-05-07
SI2610258T1 (sl)	2014-12-31
EP2610258B1 (de)	2014-08-27
UY31405A1 (es)	2009-05-29
BRPI0818006A2 (pt)	2015-12-22
EP2380891B1 (de)	2013-12-11
HK1145677A1 (zh)	2011-04-29
AU2008313660A1 (en)	2009-04-23
ZA201001683B (en)	2010-10-27
CY1115858T1 (el)	2017-01-25
ME01330B (me)	2013-12-20
EP2215092B1 (de)	2012-01-25
US20110021501A1 (en)	2011-01-27
EA019480B1 (ru)	2014-04-30
TW200918074A (en)	2009-05-01
ATE542825T1 (de)	2012-02-15
TWI421077B (zh)	2014-01-01
EP2215092A1 (de)	2010-08-11
US8754073B2 (en)	2014-06-17
MX2010004026A (es)	2010-04-30
JP2013064001A (ja)	2013-04-11
TN2010000175A1 (fr)	2011-11-11
EP2610258A1 (de)	2013-07-03

Publication	Publication Date	Title
HRP20120334T1 (hr)	2012-05-31	Supstituirani piperidino-dihidrotienopirimidini
AU2022201082B2 (en)	2023-11-02	Benzimidazole compounds as c-Kit inhibitors
ES2809533T3 (es)	2021-03-04	Derivados de imidazopiridina como moduladores de la actividad de TNF
US10562900B2 (en)	2020-02-18	Indazole compounds as FGFR kinase inhibitor, preparation and use thereof
ES2817051T3 (es)	2021-04-06	Derivados de imidazopirimidina como moduladores de la actividad de TNF
ES2810774T3 (es)	2021-03-09	Derivados de imidazopiridina como moduladores de la actividad de TNF
KR101970837B1 (ko)	2019-04-19	항바이러스제로서의 피라졸로[1,5-ａ]피리미딘
ES2775535T3 (es)	2020-07-27	Derivados de benzotriazol como moduladores de la actividad del TNF
AU2017200493A1 (en)	2017-02-16	Heterocyclyl compounds as MEK inhibitors
JP7381647B2 (ja)	2023-11-15	ｐ６２－ＺＺ化学抑制剤
EP2138489B1 (en)	2012-07-11	Novel pyrimidine compound having benzyl(heterocyclicmethyl)amine structure and pharmaceutical product containing the same
HRP20090395T1 (hr)	2009-08-31	Dihidrotienpirimidini za liječenje upalnih bolesti
BG107166A (bg)	2003-06-30	Имидазопиримидинови производни и триазолопиримидинови производни
IL276654B2 (en)	2024-01-01	Oxadiazole inhibits TRP channels
RU2623734C9 (ru)	2017-09-18	Ингибиторы киназы
IL295518A (en)	2022-10-01	Heterocyclic compounds used as pdk1 inhibitors
JP2013544261A5 (zh)	2014-01-30
NZ553886A (en)	2010-11-26	Piperidinylamino-thieno[2,3-D] pyrimidine compounds
ES2809534T3 (es)	2021-03-04	Derivados de triazolopiridazina como moduladores de la actividad de TNF
BR112014030284B1 (pt)	2021-11-30	Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
ES2866883T3 (es)	2021-10-20	Combinaciones farmacéuticas para el tratamiento del cáncer
AU2017330620A1 (en)	2019-03-28	TRPV4 antagonists
JP2023538018A (ja)	2023-09-06	ネトーシスの処置及び／又は予防における使用のための方法及び化合物
CA3090485C (en)	2024-01-16	Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases
Suryawanshi et al.	2014	Synthesis of various esters of diclofenac (NSAIDs) as pro-drugs and their biological evaluation